Original Research

DOI: 10.4244/EIJ-D-23-00658

One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes

Davide Cao1,2, MD; Pascal Vranckx3, MD; Marco Valgimigli4,5, MD, PhD; Samantha Sartori1, PhD; Dominick J. Angiolillo6, MD, PhD; Sripal Bangalore7, MD, MHA; Deepak L. Bhatt1, MD, MPH; Yihan Feng1, MS; Junbo Ge8, MD; James Hermiller9, MD; Raj R. Makkar10, MD; Franz-Josef Neumann11, MD, PhD; Shigeru Saito12, MD; Hector Picon13, MD; Ralph Toelg14, MD; Aziz Maksoud15, MD; Bassem M. Chehab16, MD; James W. Choi17, MD; Gianluca Campo18, MD; José M. De la Torre Hernandez19, MD, PhD; Mitchell W. Krucoff20, MD; Vijay Kunadian21, MD; Gennaro Sardella22, MD; Alessandro Spirito1, MD; Holger Thiele23, MD; Olivier Varenne24, MD; Birgit Vogel1, MD; Yujie Zhou25, MD; Stephan Windecker5, MD; Roxana Mehran1, MD

Abstract

BACKGROUND: A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and effective after a non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains uncertain.

AIMS: We aimed to compare the impact of 1-month versus 3-month DAPT on clinical outcomes after DES implantation among HBR patients with or without NSTE-ACS.

METHODS: This is a prespecified analysis from the XIENCE Short DAPT programme involving three prospective, international, single-arm studies evaluating the safety and efficacy of 1-month (XIENCE 28 USA and Global) or 3-month (XIENCE 90) DAPT among HBR patients after implantation of a cobalt-chromium everolimus-eluting stent. Ischaemic and bleeding outcomes associated with 1- versus 3-month DAPT were assessed according to clinical presentation using propensity score stratification.

RESULTS: Of 3,364 HBR patients (1,392 on 1-month DAPT and 1,972 on 3-month DAPT), 1,164 (34.6%) underwent DES implantation for NSTE-ACS. At 12 months, the risk of the primary endpoint of death or myocardial infarction was similar between 1- and 3-month DAPT in patients with (hazard ratio...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 10
May 20, 2024
Volume 20 Number 10
View full issue


Key metrics

On the same subject

10.4244/EIJV15I11A175 Dec 6, 2019
Short DAPT duration after ACS – not for the faint of heart
Mihatov N and Yeh R
free

Clinical research

10.4244/EIJ-D-20-00145 Oct 23, 2020
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes
Franzone A et al
free

Editorial

10.4244/EIJ-E-22-00022 Aug 19, 2022
One-month DAPT after acute coronary syndrome: too short or not too short?
Capranzano P
free

Clinical Research

10.4244/EIJ-D-21-00721 Mar 18, 2022
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
Dangas G et al
free
Trending articles
212.15

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
173.13

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
168

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
76.9

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved